PDF(982 KB)
Efficacy of chemotherapy using 10-hydroxycamptothecin on recurrent or refractory neuroblastoma in children
YUAN Zhe-Feng, TANG Yong-Min, SONG Hua, SHI Shu-Wen, YANG Shi-Long, PAN Bin-Hua, ZHAO Fen-Ying
Chinese Journal of Contemporary Pediatrics ›› 2009, Vol. 11 ›› Issue (05) : 361-363.
PDF(982 KB)
PDF(982 KB)
Efficacy of chemotherapy using 10-hydroxycamptothecin on recurrent or refractory neuroblastoma in children
OBJECTIVE: The patients with recurrent or refractory neuroblastoma have a very poor prognosis and high mortality. 10-hydroxycamptothecin (HCPT) is a new agent extracted from comptotheca acuminate, a native plant. It has been shown to be very effective in some solid tumors such as gastric and colon cancers, lung cancers and ovary cancers. However, its efficacy in neuroblastoma has not been determined. This study aimed to investigate the therapeutic effects of HCPT in the treatment of recurrent or refractory neuroblastoma in children. METHODS: Ten children with recurrent neuroblastoma and two children with refractory neuroblastoma were treated with HCPT. Of them, 5 children with recurrent neuroblastoma were treated with HCPT alone, and the other 7 patients received combination chemotherapy of HCPT plus other agents. The HCPT alone treatment group was injected with HCPT (7.5 mg/m2 daily) for 14 consecutive days. The combination chemotherapy group was alternately treated with the modified new protocol A1 (cyclophosomide 1 200 mg/m2 on day 1, etoposide 100 mg/m2 on days 1-5, HCPT 5 mg/m2 on days 1-3, cisplatin 90 mg/m2 on day 4) and the modified protocol B (ifosfomide 1.5 g/m2 on days 1-5, HCPT 5 mg/m2 on days 1-3, carboplatin 450 mg/m2 on day 2). RESULTS: Four patients (33.3%) achieved partial remission and 8 patients (66.7%) had stable disease. The median remission duration was 3.5 months (2-5 months). HCPT treatment as a single agent resulted in mild side effects. Myelosuppression and digestive disorders were found as the main adverse events in the combined chemotherapy group. No chemotherapy related deaths were found. CONCLUSIONS: HCPT is safe and effective in the treatment of recurrent or refractory neuroblastoma. The toxicities of HCPT are tolerable. The long-term efficacy of HCPT warrants further research.［Chin J Contemp Pediatr, 2009, 11 (5):361-363］
Neuroblastoma / 10-hydroxycamptothecin / Chemotherapy / Child
［1］张海燕,方军,谢小志,高宝辉.儿童恶性肿瘤275例临床病理分析［J］.中国当代儿科杂志,2002,4(4):323-324.
［2］唐锁勤,黄东生,王建文,冯晨,杨光.大剂量化疗造血干细胞移植治疗Ⅳ期神经母细胞瘤的长期疗效研究［J］.中国当代儿科杂志，2006，8（2）：93-96.
［3］高晓宁，唐锁勤，林季.晚期儿童神经母细胞瘤的临床和预后分析［J］.中国当代儿科杂志，2007，9（4）：351-354.
［4］甄子俊，孙晓非，夏 奕，王智辉，凌家瑜. 异环磷酰胺联合卡铂治疗复发和难治性神经母细胞瘤的疗效分析［J］. 癌症，2006, 25(12):1550-1552.
［5］Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification［J］. J Pediatr Hematol Oncol, 2002, 24(8):613-621.
［6］汤静燕，潘慈，陈静，徐敏，陈静，薛惠良，等. 45例儿童神经母细胞瘤预后因素分析［J］. 中华儿科杂志, 2006, 44(10):770-773.
［7］Kramer K, Kushner BH, Cheung NK. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis ［J］. J Pediatr Hematol Oncol, 2003, 25(8):601-605.
［8］Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study ［J］. J Clin Oncol, 2001, 19(15):3463-3469.
［9］Simon T, Langler A, Berthold F, Klingebiel T, Hero B. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial［J］. J Pediatr Hematol Oncol, 2007, 29(2):101-106.
［10］Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma［J］. Cancer, 2003, 98(11):2488-2494.
［11］Simon T, Langler A, Harnischmacher U, Frühwald MC, Jorch N, Claviez A, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial［J］. J Cancer Res Clin Oncol, 2007, 133(9):653-661.
［12］Kushner BH, Kramer K, Modak S, Cheung NK. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma［J］. Clin Cancer Res, 2004, 10(1 Pt 1):84-87.
［13］黄慧强，姜文奇，胡晓桦，林旭滨，刘魁凤，李宇红，等. 羟基喜树碱冻干粉针(拓僖)单药治疗晚期恶性肿瘤临床研究的初步报告［J］. 癌症, 2003, 22(12):1334-1338.
